Collectively, these results indicate that BRAF-mutated PM-CRC have persistent immune signaling leading to increased levels of BTN immune checkpoint molecules that should be further explored as a possible novel therapeutic target for this particular patient subgroup. This evidence concerns the gene BTN1A1 and colorectal carcinoma.